


BI 653048 phosphate

Cat. No.:	HY-12946A
CAS No.:	1198784-97-2
Molecular Formula:	C ₂₃ H ₂₈ F ₄ N ₃ O ₈ PS
Molecular Weight:	613.52
Target:	Glucocorticoid Receptor; Cytochrome P450; HCV Protease
Pathway:	GPCR/G Protein; Metabolic Enzyme/Protease; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	<p>BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM^[1]. BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms' activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM)^[2]. BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus^[3].</p>											
IC₅₀ & Target	CYP1A2 50 μM (IC ₅₀)	CYP2D6 41 μM (IC ₅₀)	CYP2C9 12 μM (IC ₅₀)	CYP2C19 9 μM (IC ₅₀)								
	CYP3A4 8 μM (IC ₅₀)											
In Vitro	<p>BI 653048 phosphate exhibits an improved drug-like properties, inhibits CP1A2 ,CYP2D6 ,CYP2C9, CYP2C19 and CYP3A4 with IC₅₀ values of 50 μM, 41 μM, 12 μM, 9 μM, and 8 μM, respectively^[2]. BI 653048 phosphate reduces affinity for the hERG ion channel with an IC₅₀>30 μM in recombinant HEK293 cells expressing the human ERG potassium channel^[2]. BI 653048 phosphate inhibits TNF-stimulated IL-6 production in mouse RAW cells with an IC₅₀ value of 100 nM^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>											
In Vivo	<p>BI 653048 phosphate (oral administration; 3, 10, and 30 mg/kg) at 3 mg/kg has nonsignificant decreases for all measured histology parameters (ankle inflammation, pannus formation, cartilage damage, and bone resorption), Mid-dose (10 mg/kg) treatment significantly decreases pannus and bone resorption (33%) as well as summed scores (27%), while at high dose (30 mg/kg), all parameters are significantly decreased (87–96%). The ED₅₀ value for the summed scores is 14 mg/kg^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mice^[2]</td> </tr> <tr> <td>Dosage:</td> <td>3, 10, and 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration</td> </tr> <tr> <td>Result:</td> <td>Exhibited significant decreases for all measured histology parameters at high doses.</td> </tr> </table>				Animal Model:	Mice ^[2]	Dosage:	3, 10, and 30 mg/kg	Administration:	Oral administration	Result:	Exhibited significant decreases for all measured histology parameters at high doses.
Animal Model:	Mice ^[2]											
Dosage:	3, 10, and 30 mg/kg											
Administration:	Oral administration											
Result:	Exhibited significant decreases for all measured histology parameters at high doses.											

REFERENCES

- [1]. Reeves JT, et al. Development of a large scale asymmetric synthesis of the glucocorticoid agonist BI 653048 BS H3PO4. J Org Chem. 2013 Apr 19;78(8):3616-35.
- [2]. Harcken C, et al. Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate. ACS Med Chem Lett. 2014 Nov 20;5(12):1318-23.
- [3]. Montse Llinas-Brunet, et al. Latest bibliographic data on file with the International Bureau
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA